Schall, Brown & Schwartz LLP is reminding investors about a securities class action against Aardvark Therapeutics, Inc. over alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, a securities-fraud rule enforced by the U.S. Securities and Exchange Commission. The complaint alleges that Aardvark misrepresented ARD-101’s safety profile and overstated the drug candidate’s clinical and commercial prospects, making the company’s public statements materially misleading during the IPO period. The proposed class covers investors whose purchases were pursuant to or traceable to Aardvark’s February 13, 2025, IPO and investors who bought shares from February 13, 2025, through May 14, 2026. The deadline to contact the firm is October 13, 2026. Appointment as lead plaintiff is not required to participate in any recovery. The class has not yet been certified, and investors are not represented by an attorney unless certification occurs; those who take no action may remain absent class members.